FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203310487> ?p ?o ?g. }

• W3203310487 endingPage "530" @default.
• W3203310487 startingPage "524" @default.
• W3203310487 abstract "Aromatase inhibitors have been used empirically to treat a subset of patients with hormone receptor positive uterine leiomyosarcomas(LMS) and carcinosarcomas (UCS) mainly supported by retrospective data. We evaluated the activity of anastrozole in two rare cohorts; patients with recurrent/metastatic LMS and UCS enrolled in PARAGON, a basket trial of anastrozole in estrogen receptor (ER+)/progesterone receptor positive (PR+) gynecological cancers.An investigator-initiated, single-arm, prospective open-label trial of anastrozole 1 mg/day in patients with ER &/or PR + ve LMS or UCS with measurable disease, treated until progression or unacceptable toxicity. Primary endpoint was clinical benefit (complete/partial response + stable disease) rate (CBR) at 3 months. Secondary endpoints include progression-free survival (PFS), quality of life and toxicity.39 eligible patients were enrolled, 32 with LMS and 7 with UCS. For the LMS cohort CBR at 3 months was 35% (95% CI: 21-53%) with a median duration of clinical benefit of 5.8 months. Best response was a partial response in one patient. Two patients remained on treatment for more than one year. The median progression-free survival was 2.8 months (95% CI: 2.6-4.9). For the UCS cohort CBR at 3 months was 43% (95% CI: 16-75%) with a median duration of clinical benefit of 5.6 months. Stable disease was seen in 3 patients but no objective responses were seen. The median progression-free survival was 2.7 months (95% CI, 1.1-8.2). Safety was acceptable with 5/39 evaluable patients showing grade 3 toxicities.Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS." @default.
• W3203310487 created "2021-10-11" @default.
• W3203310487 creator A5001026176 @default.
• W3203310487 creator A5003031523 @default.
• W3203310487 creator A5003079638 @default.
• W3203310487 creator A5008590899 @default.
• W3203310487 creator A5011119212 @default.
• W3203310487 creator A5012143202 @default.
• W3203310487 creator A5021894535 @default.
• W3203310487 creator A5022103886 @default.
• W3203310487 creator A5035319166 @default.
• W3203310487 creator A5038850730 @default.
• W3203310487 creator A5051483869 @default.
• W3203310487 creator A5051689511 @default.
• W3203310487 creator A5056093407 @default.
• W3203310487 creator A5056772784 @default.
• W3203310487 creator A5058371392 @default.
• W3203310487 creator A5063000325 @default.
• W3203310487 creator A5065447416 @default.
• W3203310487 creator A5067031252 @default.
• W3203310487 creator A5071781603 @default.
• W3203310487 creator A5086079214 @default.
• W3203310487 date "2021-12-01" @default.
• W3203310487 modified "2023-10-18" @default.
• W3203310487 title "Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)" @default.
• W3203310487 cites W1502045029 @default.
• W3203310487 cites W1593008823 @default.
• W3203310487 cites W1966987047 @default.
• W3203310487 cites W1976710676 @default.
• W3203310487 cites W1987085807 @default.
• W3203310487 cites W1987450118 @default.
• W3203310487 cites W1994542541 @default.
• W3203310487 cites W1997197477 @default.
• W3203310487 cites W2004001144 @default.
• W3203310487 cites W2020018978 @default.
• W3203310487 cites W2029612031 @default.
• W3203310487 cites W2030505692 @default.
• W3203310487 cites W2031058307 @default.
• W3203310487 cites W2033713913 @default.
• W3203310487 cites W2034275482 @default.
• W3203310487 cites W2085343865 @default.
• W3203310487 cites W2093708109 @default.
• W3203310487 cites W2096755839 @default.
• W3203310487 cites W2097881410 @default.
• W3203310487 cites W2101776780 @default.
• W3203310487 cites W2103607521 @default.
• W3203310487 cites W2314973812 @default.
• W3203310487 cites W2387879652 @default.
• W3203310487 cites W2425983220 @default.
• W3203310487 cites W2488456052 @default.
• W3203310487 cites W2581250410 @default.
• W3203310487 cites W2593909874 @default.
• W3203310487 cites W2595991414 @default.
• W3203310487 cites W2613173998 @default.
• W3203310487 cites W2752560124 @default.
• W3203310487 cites W2754568820 @default.
• W3203310487 cites W2787725515 @default.
• W3203310487 cites W2891531638 @default.
• W3203310487 cites W2904093244 @default.
• W3203310487 cites W2942634811 @default.
• W3203310487 cites W2944491524 @default.
• W3203310487 cites W2946195245 @default.
• W3203310487 cites W2953373767 @default.
• W3203310487 cites W3033077210 @default.
• W3203310487 cites W3130727530 @default.
• W3203310487 cites W3193709867 @default.
• W3203310487 doi "https://doi.org/10.1016/j.ygyno.2021.09.010" @default.
• W3203310487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34625284" @default.
• W3203310487 hasPublicationYear "2021" @default.
• W3203310487 type Work @default.
• W3203310487 sameAs 3203310487 @default.
• W3203310487 citedByCount "3" @default.
• W3203310487 countsByYear W32033104872022 @default.
• W3203310487 crossrefType "journal-article" @default.
• W3203310487 hasAuthorship W3203310487A5001026176 @default.
• W3203310487 hasAuthorship W3203310487A5003031523 @default.
• W3203310487 hasAuthorship W3203310487A5003079638 @default.
• W3203310487 hasAuthorship W3203310487A5008590899 @default.
• W3203310487 hasAuthorship W3203310487A5011119212 @default.
• W3203310487 hasAuthorship W3203310487A5012143202 @default.
• W3203310487 hasAuthorship W3203310487A5021894535 @default.
• W3203310487 hasAuthorship W3203310487A5022103886 @default.
• W3203310487 hasAuthorship W3203310487A5035319166 @default.
• W3203310487 hasAuthorship W3203310487A5038850730 @default.
• W3203310487 hasAuthorship W3203310487A5051483869 @default.
• W3203310487 hasAuthorship W3203310487A5051689511 @default.
• W3203310487 hasAuthorship W3203310487A5056093407 @default.
• W3203310487 hasAuthorship W3203310487A5056772784 @default.
• W3203310487 hasAuthorship W3203310487A5058371392 @default.
• W3203310487 hasAuthorship W3203310487A5063000325 @default.
• W3203310487 hasAuthorship W3203310487A5065447416 @default.
• W3203310487 hasAuthorship W3203310487A5067031252 @default.
• W3203310487 hasAuthorship W3203310487A5071781603 @default.
• W3203310487 hasAuthorship W3203310487A5086079214 @default.
• W3203310487 hasConcept C121608353 @default.
• W3203310487 hasConcept C126322002 @default.
• W3203310487 hasConcept C143998085 @default.
• W3203310487 hasConcept C188816634 @default.

• next